As on 24 Apr 2025

Tata India Pharma & Healthcare Fund-Direct Plan-Growth
EquityNAV
₹ 34.51
CAGR (3 Years)
21.87%
AUM (Cr)
₹ 1,183.65
Risk
Very High Risk
About Tata India Pharma & Healthcare Fund-Direct Plan-Growth
To seek long term capital appreciation by investing at least 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sector in India.
Breakdown of this Fund
Chemicals
0.60%
Debt Others
6.17%
Fertilizers
1.91%
Healthcare
47.41%
Insurance
3.32%
IT - Software
1.22%
Pharmaceuticals
105.83%
Retail
1.53%
Market Capitalization
Expense Ratio, Exit Load and Tax
Expense Ratio
0.1
Exit Load
0.50% - If redeemed\switched out within 30 days from the date of allotment. Nil ...
Stamp Duty
0.005% (from July 1st, 2020)
Tax Implication
Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.